Peter Steiner
Fundador en PreComb Therapeutics AG .
Relaciones activas
| Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
|---|---|---|---|---|
| Klaus Mauch | M | - |
Insilico Biotechnology AG
 Insilico Biotechnology AG Packaged SoftwareTechnology Services Part of Yokogawa Electric Corp., Insilico Biotechnology AG is a German company that develops software for biotechnology. The company is based in Stuttgart, Germany. The company was founded in 2001 by Klaus Mauch. Klaus Mauch has been the CEO since 2001. Insilico Biotechnology was acquired by Yokogawa Electric Corp. on November 02, 2021 for $30.14 million. | 23 años |
| Jens M. Kelm | M | - |
PreComb Therapeutics AG
 PreComb Therapeutics AG Pharmaceuticals: MajorHealth Technology PreComb Therapeutics AG is a Swiss company that specializes in functional precision medicine for oncology and cancer. The company is based in Hombrechtikon, Switzerland. The company uses organoid and predictive technologies, as well as AI and data mining, to guide therapy and automate processes. The company also works in immune oncology and collaborate with other organizations such as 2curex, Xilis, USZ, DKFZ, and NCT. The company was founded in 2018 by Peter Steiner and Jens M. Kelm, with Jens M. Kelm serving as CEO since then. | - |
| Johannes Roth | M | 44 |
Insilico Biotechnology AG
Insilico Biotechnology AG Packaged SoftwareTechnology Services Part of Yokogawa Electric Corp., Insilico Biotechnology AG is a German company that develops software for biotechnology. The company is based in Stuttgart, Germany. The company was founded in 2001 by Klaus Mauch. Klaus Mauch has been the CEO since 2001. Insilico Biotechnology was acquired by Yokogawa Electric Corp. on November 02, 2021 for $30.14 million. | - |
| Patrick Aisher | M | 53 |
PreComb Therapeutics AG
PreComb Therapeutics AG Pharmaceuticals: MajorHealth Technology PreComb Therapeutics AG is a Swiss company that specializes in functional precision medicine for oncology and cancer. The company is based in Hombrechtikon, Switzerland. The company uses organoid and predictive technologies, as well as AI and data mining, to guide therapy and automate processes. The company also works in immune oncology and collaborate with other organizations such as 2curex, Xilis, USZ, DKFZ, and NCT. The company was founded in 2018 by Peter Steiner and Jens M. Kelm, with Jens M. Kelm serving as CEO since then. | - |
| Bertram Layer | M | - |
Insilico Biotechnology AG
Insilico Biotechnology AG Packaged SoftwareTechnology Services Part of Yokogawa Electric Corp., Insilico Biotechnology AG is a German company that develops software for biotechnology. The company is based in Stuttgart, Germany. The company was founded in 2001 by Klaus Mauch. Klaus Mauch has been the CEO since 2001. Insilico Biotechnology was acquired by Yokogawa Electric Corp. on November 02, 2021 for $30.14 million. | - |
| Lothar Terfloth | M | - |
Insilico Biotechnology AG
Insilico Biotechnology AG Packaged SoftwareTechnology Services Part of Yokogawa Electric Corp., Insilico Biotechnology AG is a German company that develops software for biotechnology. The company is based in Stuttgart, Germany. The company was founded in 2001 by Klaus Mauch. Klaus Mauch has been the CEO since 2001. Insilico Biotechnology was acquired by Yokogawa Electric Corp. on November 02, 2021 for $30.14 million. | - |
Gráfico relacional
Relaciones con varias empresas
Antiguas relaciones
| Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
|---|---|---|---|---|
| Thomas O. Hecht | M | 73 |
ESBATech, a Novartis Co. GmbH
 ESBATech, a Novartis Co. GmbH Miscellaneous Commercial ServicesCommercial Services ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland. | 5 años |
| James J. Egan | M | 73 |
ESBATech, a Novartis Co. GmbH
ESBATech, a Novartis Co. GmbH Miscellaneous Commercial ServicesCommercial Services ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland. | 3 años |
| Martin Gertsch | M | 59 |
ESBATech, a Novartis Co. GmbH
ESBATech, a Novartis Co. GmbH Miscellaneous Commercial ServicesCommercial Services ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland. | 2 años |
| Peter Lichtlen | M | 56 |
ESBATech, a Novartis Co. GmbH
ESBATech, a Novartis Co. GmbH Miscellaneous Commercial ServicesCommercial Services ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland. | 9 años |
| Anne Schmidt | M | - |
ESBATech, a Novartis Co. GmbH
ESBATech, a Novartis Co. GmbH Miscellaneous Commercial ServicesCommercial Services ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland. | - |
| Jürgen E. Bader | M | - |
ESBATech, a Novartis Co. GmbH
ESBATech, a Novartis Co. GmbH Miscellaneous Commercial ServicesCommercial Services ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland. | - |
| Rouven Bingel-Erlenmeyer | M | - |
ESBATech, a Novartis Co. GmbH
ESBATech, a Novartis Co. GmbH Miscellaneous Commercial ServicesCommercial Services ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland. | - |
| Ulrich Bauer | M | - |
ESBATech, a Novartis Co. GmbH
ESBATech, a Novartis Co. GmbH Miscellaneous Commercial ServicesCommercial Services ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland. | - |
| Christian Leisner | M | - |
ESBATech, a Novartis Co. GmbH
ESBATech, a Novartis Co. GmbH Miscellaneous Commercial ServicesCommercial Services ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland. | - |
Estadísticas
| País | Relaciones | % del total |
|---|---|---|
| Suiza | 11 | 73.33% |
| Alemania | 4 | 26.67% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- Peter Steiner
- Red Personal
